Commitments and Contingencies (Details) - License Agreements [Member] - USD ($) $ in Thousands |
Jan. 31, 2025 |
Apr. 08, 2016 |
|---|---|---|
| Commitments and Contingencies [Line Items] | ||
| Issuance of shares | 277,823 | 882,353 |
| License upfront fee paid | $ 70 | |
| Percentage of patent net sales | 3.50% | |
| Percentage royalty of net sales | 1.75% | |
| Percentage of sublicensee’s net sales | 1.75% | |
| Percentage of non-royalty consideration | 7.50% | |
| Other expenses | $ 50 | |
| Milestones for orphan indication | $ 75 | |
| Milestones for a non-orphan indication | $ 650 | |
| Food and Drug Administration [Member] | ||
| Commitments and Contingencies [Line Items] | ||
| Other expenses | $ 100 |
| X | ||||||||||
- Definition The amount of license upfront fee. No definition available.
|
| X | ||||||||||
- Definition The amount of milestones for a non-orphan indication. No definition available.
|
| X | ||||||||||
- Definition The amount of milestones for orphan indication. No definition available.
|
| X | ||||||||||
- Definition Percentage of non-royalty consideration. No definition available.
|
| X | ||||||||||
- Definition The percentage of patent net sales. No definition available.
|
| X | ||||||||||
- Definition The percentage of sublicensee’s net sales. No definition available.
|
| X | ||||||||||
- Definition The percentage of royalty. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|